150459-78-2

Basic information

• Product Name: 5,6,7,8-Tetrahydroquinoline-2-carbonitrile
• Synonyms: 5,6,7,8-Tetrahydroquinoline-2-carbonitrile
• CAS NO: 150459-78-2
• Molecular Formula: C10H10N2
• Molecular Weight: 158.1998
• Mol File: 150459-78-2.mol

Chemical Properties

• Boiling Point: 297.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.75±0.20(Predicted)
• CAS DataBase Reference: 5,6,7,8-Tetrahydroquinoline-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-Tetrahydroquinoline-2-carbonitrile(150459-78-2)
• EPA Substance Registry System: 5,6,7,8-Tetrahydroquinoline-2-carbonitrile(150459-78-2)

Safety Data

• Hazardous Substances Data: 150459-78-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5,6,7,8-Tetrahydroquinoline-2-carbonitrile is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its versatile reactivity allows for the creation of a wide range of heterocyclic compounds, which are essential in the development of new drugs and therapeutic agents.
Used in Drug Discovery and Development:
As a valuable intermediate, 5,6,7,8-Tetrahydroquinoline-2-carbonitrile is utilized in drug discovery and development processes. Its potential biological activities make it a promising candidate for the creation of new therapeutic agents, particularly in the areas of antitumor and antioxidant research.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5,6,7,8-Tetrahydroquinoline-2-carbonitrile is studied for its potential antitumor and antioxidant properties. Its significance lies in the exploration of new chemical entities that can contribute to the advancement of treatments for various diseases and conditions.
Used in Chemical Compound Production:
5,6,7,8-Tetrahydroquinoline-2-carbonitrile is also used in the production of various chemical compounds, particularly those with heterocyclic structures. Its role in this industry is to provide a foundation for the synthesis of complex molecules that can be further utilized in a range of applications, from pharmaceuticals to specialty chemicals.

Upstream product

• 14631-48-2 5,6,7,8-tetrahydroquinoline N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 10500-57-9 5,6,7,8-tetrahydroquinoline 

Relevant articles and documents

Water-soluble inhibitors of ABCG2 (BCRP) – A fragment-based and computational approach

A good balance between hydrophilicity and lipophilicity is a prerequisite for all bioactive compounds. If the hydrophilicity of a compound is low, its solubility in water will be meager. Many drug development failures have been attributed to poor aqueous solubility. ABCG2 inhibitors are especially prone to be insoluble since they have to address the extremely large and hydrophobic multidrug binding site in ABCG2. For instance, our previous, tariquidar-related ABCG2 inhibitor UR-MB108 (1) showed high potency (79 nM), but very low aqueous solubility (78 nM). To discover novel potent ABCG2 inhibitors with improved solubility we pursued a fragment-based approach. Substructures of 1 were optimized and the fragments ‘enlarged’ to obtain inhibitors, supported by molecular docking studies. Synthesis was achieved, i.a., via Sonogashira coupling, click chemistry and amide coupling. A kinetic solubility assay revealed that 1 and most novel inhibitors did not precipitate during the short time period of the applied biological assays. The solubility of the compounds in aqueous media at equilibrium was investigated in a thermodynamic solubility assay, where UR-Ant116 (40), UR-Ant121 (41), UR-Ant131 (48) and UR-Ant132 (49) excelled with solubilities between 1 μM and 1.5 μM – an up to 19-fold improvement compared to 1. Moreover, these novel N-phenyl-chromone-2-carboxamides inhibited ABCG2 in a Hoechst 33342 transport assay with potencies in the low three-digit nanomolar range, reversed MDR in cancer cells, were non-toxic and proved stable in blood plasma. All properties make them attractive candidates for in vitro assays requiring long-term incubation and in vivo studies, both needing sufficient solubility at equilibrium. 41 and 49 were highly ABCG2-selective, a precondition for developing PET tracers. The triple ABCB1/C1/G2 inhibitor 40 qualifies for potential therapeutic applications, given the concerted role of the three transporter subtypes at many tissue barriers, e.g. the BBB.

HCV PROTEASE INHIBITORS

This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection.

1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF

This invention provides a compound represented by the formula (I) :wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents;R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents;n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

Synthetic studies on thiostrepton family of peptide antibiotics: Synthesis of the tetrasubstituted dihydroquinoline portion of siomycin D1

The tetrasubstituted dihydroquinoline portion of siomycin D1, a member of the thiostrepton family of peptide antibiotics, was synthesized from 5,6,7,8-tetrahydroquinoline featuring the modified Reissert-Henze reaction, the homolytic aromatic su

A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair

The structure-activity relationship of a series of styrylpyridine analogs of MK-0476 (montelukast, Singular) is described. This work has led to the identification of a number of potent and orally active cysLT1 receptor (LTD4 receptor) antagonists including 2ab (L-733,321) as an optimized candidate.